Predicting Neoadjuvant Chemotherapy Response and High-Grade Serous Ovarian Cancer From CT Images in Ovarian Cancer with Multitask Deep Learning: A Multicenter Study.

[1]  W. Wang,et al.  Predicting peritoneal recurrence and disease-free survival from CT images in gastric cancer with multitask deep learning: a retrospective study. , 2022, The Lancet. Digital health.

[2]  Hui-Ni Chen,et al.  Deep Learning Prediction of Ovarian Malignancy at US Compared with O-RADS and Expert Assessment. , 2022, Radiology.

[3]  Yan Liu,et al.  Deep learning-enabled pelvic ultrasound images for accurate diagnosis of ovarian cancer in China: a retrospective, multicentre, diagnostic study. , 2022, The Lancet. Digital health.

[4]  L. Schwartz,et al.  Deep learning for the prediction of early on-treatment response in metastatic colorectal cancer from serial medical imaging , 2021, Nature Communications.

[5]  M. Bae,et al.  Breast Cancer Risk Prediction Using Deep Learning. , 2021, Radiology.

[6]  Jakob Nikolas Kather,et al.  Gastrointestinal cancer classification and prognostication from histology using deep learning: Systematic review. , 2021, European journal of cancer.

[7]  S. Kehoe,et al.  Neoadjuvant chemotherapy before surgery versus surgery followed by chemotherapy for initial treatment in advanced ovarian epithelial cancer. , 2021, The Cochrane database of systematic reviews.

[8]  Ruijiang Li,et al.  Radiographical assessment of tumour stroma and treatment outcomes using deep learning: a retrospective, multicohort study. , 2021, The Lancet. Digital health.

[9]  Jianbo Wang,et al.  Deep learning-based six-type classifier for lung cancer and mimics from histopathological whole slide images: a retrospective study , 2021, BMC Medicine.

[10]  Ruijiang Li,et al.  Predicting treatment response from longitudinal images using multi-task deep learning , 2021, Nature Communications.

[11]  X. Cui,et al.  Ultrasound-based deep learning radiomics in the assessment of pathological complete response to neoadjuvant chemotherapy in locally advanced breast cancer. , 2021, European journal of cancer.

[12]  D. Chi,et al.  Advanced ovarian cancer and cytoreductive surgery: Independent validation of a risk-calculator for perioperative adverse events. , 2020, Gynecologic oncology.

[13]  A. Kumari,et al.  To compare the optimal cytoreduction rate in advanced epithelial ovarian cancer stage III/IV after 3 versus 6 cycles of neoadjuvant chemotherapy , 2020, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[14]  E. Sala,et al.  Does the method of primary treatment affect the pattern of first recurrence in high-grade serous ovarian cancer? , 2019, Gynecologic oncology.

[15]  A. Oza,et al.  Epithelial ovarian cancer: Evolution of management in the era of precision medicine , 2019, CA: a cancer journal for clinicians.

[16]  A. Oza,et al.  Epithelial ovarian cancer , 2019, The Lancet.

[17]  Raymond Y Huang,et al.  Artificial intelligence in cancer imaging: Clinical challenges and applications , 2019, CA: a cancer journal for clinicians.

[18]  Y. Song,et al.  Neoadjuvant chemotherapy in advanced ovarian cancer: optimal patient selection and response evaluation. , 2018, Chinese clinical oncology.

[19]  R. Edwards,et al.  Diagnosis and Treatment of Ovarian Cancer. , 2018, Hematology/oncology clinics of North America.

[20]  A. Ivantsov.  Pathological response of ovarian cancer to neoadjuvant chemotherapy. , 2018, Chinese clinical oncology.

[21]  Ahmed Hosny,et al.  Artificial intelligence in radiology , 2018, Nature Reviews Cancer.

[22]  D. Armstrong.  New Therapies for Ovarian Cancer. , 2018, Journal of the National Comprehensive Cancer Network : JNCCN.

[23]  T. Kasamatsu,et al.  Comparison of treatment invasiveness between upfront debulking surgery versus interval debulking surgery following neoadjuvant chemotherapy for stage III/IV ovarian, tubal, and peritoneal cancers in a phase III randomised trial: Japan Clinical Oncology Group Study JCOG0602. , 2016, European journal of cancer.

[24]  Erich P Huang,et al.  RECIST 1.1-Update and clarification: From the RECIST committee. , 2016, European journal of cancer.

[25]  H. Kitchener,et al.  Primary chemotherapy versus primary surgery for newly diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-inferiority trial , 2015, The Lancet.

[26]  Shuang Dong,et al.  HOTAIR is a predictive and prognostic biomarker for patients with advanced gastric adenocarcinoma receiving fluorouracil and platinum combination chemotherapy. , 2015, American journal of translational research.

[27]  N. Avril,et al.  New ways of assessing ovarian cancer response: metabolic imaging and beyond , 2012, Cancer imaging : the official publication of the International Cancer Imaging Society.

[28]  Y. Yıldırım,et al.  The predictors of response to neoadjuvant chemotherapy in advanced epithelial ovarian cancer , 2012, Journal of surgical oncology.

[29]  G. Kenter,et al.  Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. , 2010, The New England journal of medicine.

[30]  A. du Bois,et al.  Future options for first-line therapy of advanced ovarian cancer , 2005, International Journal of Gynecologic Cancer.

[31]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[32]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.